Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.
Molife LR, Yan L, Vitfell-Rasmussen J, Zernhelt AM, Sullivan DM, Cassier PA, Chen E, Biondo A, Tetteh E, Siu LL, Patnaik A, Papadopoulos KP, de Bono JS, Tolcher AW, Minton S.
Molife LR, et al. Among authors: chen e.
J Hematol Oncol. 2014 Jan 3;7:1. doi: 10.1186/1756-8722-7-1.
J Hematol Oncol. 2014.
PMID: 24387695
Free PMC article.
Clinical Trial.